In Vitro Screening of Interventional Agents in High Throughput Screening (HTS) Formats: High Throughput Screening to Identify HIV Inhibitors

高通量筛选 (HTS) 形式的介入药物体外筛选：通过高通量筛选识别 HIV 抑制剂

• 批准号: 10223949
• 负责人: SUSAN SCHADER
• 金额: $ 11.53万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10223949
• 关键词: Academia; Cells; Chemicals; Contracts; Development; Gene Expression; HIV; HIV Infections; In Vitro; Intervention; Libraries; Local Microbicides; National Institute of Allergy and Infectious Disease; Private Sector; Public Health; Resources; Source; Therapeutic; high throughput screening; in vitro testing; inhibitor/antagonist; novel therapeutics; preclinical development; public health priorities; screening

In Vitro Testing Resource for HIV Therapeutics and Topical Microbicides: The development and introduction of new therapeutics and topical microbicides against HIV remains a high public health priority. To assist in filling these public health gaps, the NIAID supports preclinical development of promising therapeutic and topical microbicide candidates that emerge from academia, the private sector, or other sources. This contract provides in vitro testing, in standard and HTS formats, and conducts preclinical development studies to identify promising anti‐HIV therapeutics and topical microbicides.

HIV治疗药物和局部杀微生物剂的体外测试资源：开发和引入针对HIV的新治疗药物和局部杀微生物剂仍然是公共卫生的高度优先事项。为了帮助填补这些公共卫生空白，NIAID支持来自学术界，私营部门或其他来源的有前途的治疗和局部杀微生物剂候选物的临床前开发。该合同以标准和HTS形式提供体外测试，并进行临床前开发研究，以确定有前途的抗HIV治疗药物和局部杀微生物剂。